"We believe the financing facility we recently put into place will provide us with flexibility and an additional option for funding our continued growth.”
What is that growth rate over time THEY speak of? Why are they so tight lipped? Why are the experts not expounding the virtues of the Nephros technology?
Stay away from these thieves.
Holding to sue.
Heavy stuff, but I'll bite. What/Who is your source? Will the partnership you reference be announced at the same time ISIS declares world peace?:)
Amron, Davidson, meiyal,et al control this company, and have for a long time. They've never hired an effective team. Says volumes about them.
We will see soon where it goes.
Are you insinuating this is going to $3.00 now that it has hit below $1.90?
This is going to zero, that's my bet.
U pump bag dude.
I think MT said they are up to 45 sites enrolled(there were 39 as of 5/5/15). 6 sites in 3 months. I realize China is targeted for the heaviest enrollment(21 hospitals), but how can they proclaim to be recruiting heavily in North America? The statement was made last November, but per clinical trial site they show two hospitals in NA. UCLA in California and Toronto General in Canada.
HEAT study had 9 from USA and 2 in Canada.
Only point is, at times it seems their words are overly optimistic or misleading.
In their own words from 11/5/14 pr:
US-based oncology firm Celsion has received approval via Europe's centralised Voluntary Harmonization Procedure (VHP) to conduct the Phase III OPTIMA trial of ThermoDox in primary liver cancer, also known as hepatocellular carcinoma (HCC), in Europe.
The trial is designed to evaluate ThermoDox in combination with radiofrequency ablation standardised to 45 minutes (sRFA) versus sRFA alone to treat patients with non-resectable HCC lesions.
ThermoDox is the company's proprietary heat-activated liposomal encapsulation of doxorubicin.
Around 550 patients globally are expected to be enrolled in the Phase III trial, in up to 100 clinical sites in the US, Europe, China and Asia Pacific.
"We are aggressively recruiting patients at sites in North America and the Asia Pacific region."
Apart from Italy, the global pivotal, double-blind, placebo-controlled Phase III OPTIMA trial will now include sites in Spain and Germany.
The OPTIMA trial is recruiting and enrolling patients at sites in the US, Hong Kong, South Korea, Malaysia and Thailand.
The company intends to start patient enrolment at additional clinical sites in Canada, Taiwan, and Philippines before the end of this year, while the regulatory approval from the China FDA (CFDA) is expected to follow in EARLY 2015.
As Maxwell Smart would say, "missed it by that much". Unfortunately, this isn't a comedy show.
Makes one wonder about Churchs statement during the last cc that they have enough cash to last 22-24 months. As analyst Jason Colbert noted during the cc, it doesn't add up, to which church commented, we can talk off air after the call.
Background: Children on conventional haemodialysis (HD) have a 1000-fold higher mortality than their healthy peers and can have malnutrition and growth retardation. Haemodiafiltration (HDF) achieves better clearance of uraemic solutes across a wide molecular-weight range and performs greater ultrafiltration than conventional HD. Randomised controlled trials in adults have shown 35-45% improved survival and reduced cardiovascular mortality on HDF with high convection volumes. Excellent catch-up growth has been demonstrated in children on HDF, but mechanisms are poorly understood.
Hypothesis: HDF improves the cardiovascular risk profile, growth and quality of life (QoL) compared to conventional HD. Primary outcome measures are carotid intima-media thickness (cIMT) and height standard deviation score (SDS).
Plan of investigation: Incident and prevalent patients on HDF or HD who are expected to remain on dialysis for 6-months and who have a single pool Kt/v 1.2 will be compared in a 1:1 study design. Anthropometric measures (height SDS, body mass index SDS) and QoL questionnaires will be monitored at baseline and 6-monthly. Cardiovascular measures (cIMT, pulse wave velocity, left ventricular mass index and 24-hour BP) will be measured annually. 6-monthly blood tests will measure nutritional biomarkers, mineral dysregulation, inflammation and middle-molecule clearance. Outcome measures will be standardised to the convective clearance dose per m2 body surface area. Recruitment will continue for 2½ years with minimum follow-up of 6-months.
Children will be recruited from all UK dialysis units, but small patient numbers (10-12/year) necessitate collaborations with European centres. HDF and HD patients across Europe who are part of the Cardiovascular Comorbidity in Childhood CKD (4C) study will be included and vascular scans will be captured from this study. From ESPN/ERA-EDTA registry data we estimate ~100 children on HDF over the study period.
Outcomes: If the 3H (HDF
Institutional investors have vastly increased holdings as reported for the last quarter(period ending 6/30/15). Increased activity as of yesterday is 1,157,721. Decreased in that same period, as of yesterday, is 1,433. Increase/decrease ratio = 1157721/1433= 807.90.
807.90x100 = 80,790% increase.
Many companies unreported to date.
My take is positive.
Did they mean to say .006(not .06) vs .0198? That would be a "doubling of improvement" by my gauge.
Any statisticians out there? Great news, but why is the Chinese p-value(.06) higher than the overall group p-value of .0198?
So, I can't find your reference on Celsion's web page under LISTED presentations? They have many.
Why must I have to go to stocktwits(that name alone doesn't garner confidence)?
I'm more familiar with this company than I care to admit. Where, exactly, on their website is the available info you note?
Six years and, frustratingly, holding(my arms hurt;)
Not sure what you are saying, other than, perhaps, time will prove them frauds?
Will not argue against that.
A 15 year "shareholder".
There's no one like Merlin. there's no one like Merlin....
Never mind a week, it's been a LONG time. As I've said before, MT uses words like "robust" and "curative" often. At this point, his (and others) salary is(are) the only reason the word robust should be used when describing this company. Other than (retail investors), few are buying his pitch.
Comes down to the Lynch's vs. the O'Neil's.
" Whether institutional ownership in a stock is a good thing remains a matter of debate. Peter Lynch, in his best-seller "One Up on Wall Street" lists the 13 characteristics of the perfect stock. One of them is this: "Institutions don't own it and the analysts don't follow it". Lynch favors stocks that the big investment groups overlook because these stocks have more of a chance of being undervalued. Lynch argues that companies whose stock is owned by institutional investors are fairly valued, if not overvalued.
William O'Neil, founder of Investor's Business Daily, on the other hand, argues that it takes a significant amount of demand to move a share price up, and the largest source of demand for stocks are institutional investors. O'Neil reckons that if a stock has no institutional owners, it's because they have already seen it and rejected it. In his book "How to Make Money in Stocks", O'Neil has institutional sponsorship as the sixth characteristic to look for in stocks worth buying."
I think you agree with me, correct? Educate me, what does PCORI stand for(too lazy to search at this hour)?
For whatever reason, Nephros(LAMBDA) has never pushed hard after the initial public offering when Ron Perelman sunk a ton.
That said, did Perelman ever sell? I've never seen a filing stating he has ever sold?
Arthur Amron, what you say?
Thank God for FOIA.
Neither Fresenius nor DaVita are inclined to jump into the USA market of HDF as long as ESO(erythropoietin) is reimbursed so heavily by the government. Nephros' HDF treatments cut WAY DOWN on ESO usage.
Talk to hour congressman.
Have you no trust with ymb(yahoo message board) participants? Why the side bar at stocktwits?
Please, openly explain.
B4, birdzeee, your opinions please.